Zobrazeno 1 - 10
of 10
pro vyhledávání: '"I A Vilyum"'
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 1, Pp 4-21 (2020)
Objective. To determine the pharmacoeconomical feasibility of using a combination of atezolizumab + nab-paclitaxel in the 1st line of therapy for locally advanced or metastatic triple negative breast cancer (TNBC) in adult PDL1 positive patients in t
Externí odkaz:
https://doaj.org/article/547b6835489f46afa9c36e6ec461c397
Publikováno v:
Фармакоэкономика, Vol 11, Iss 2, Pp 9-24 (2018)
The aim: to provide a comprehensive pharmacoeconomic evaluation of the maintenance therapy with antipsychotics in outpatients diagnosed with schizophrenia.Materials and methods. The analysis was conducted by two mutually complementary steps: an epide
Externí odkaz:
https://doaj.org/article/094d3225e6b242498f966c50a5aeba23
Publikováno v:
Фармакоэкономика, Vol 11, Iss 1, Pp 3-18 (2018)
The aim: to provide a comprehensive pharmacoeconomic evaluation of the antipsychotic maintenance therapy in outpatients diagnosed with schizophrenia.Materials and methods. The analysis was conducted in two mutually complementary stages: an epidemiolo
Externí odkaz:
https://doaj.org/article/169921cec19b49b6a2a4e9d49e659405
Autor:
A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum
Publikováno v:
Фармакоэкономика, Vol 9, Iss 1, Pp 34-38 (2016)
Background: In 2014 we firstly analyzed the formalized system (points and expert opinions) of drug inclusion and exclusion into the reimbursement lists in Russian Federation. The liner mathematical model of decision making was developed and adopted.A
Externí odkaz:
https://doaj.org/article/f1931e909f9940e6a6b831cdcbde316e
Publikováno v:
Фармакоэкономика, Vol 8, Iss 1, Pp 39-46 (2015)
We have performed the first-ever Budget Impact Analysis (BIA) in a Russian context of bendamustine in the first line of therapy of a multiple myeloma for patients more senior 65 years old with clinical manifestations of a polineuropathy, which autolo
Externí odkaz:
https://doaj.org/article/8f73b1c0901a43a691bdfbc77bb656ad
Publikováno v:
Фармакоэкономика, Vol 6, Iss 4, Pp 26-34 (2015)
for the first time in the Russian conditions the pharmacoeconomic analysis examined the application dalteparin in comparison with other low-molecular-weight heparins in patients with high risk of venous tromboembolism at the multifield hospital. On t
Externí odkaz:
https://doaj.org/article/054558b673f5453b8eddee0212a522c4
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 4, Pp 33-43 (2019)
Pompe disease (PD) — a rare disease with progressive muscles weakness, cardiac and pulmonary insufficiency and others vital life-threatening symptoms without enzyme replacement therapy (ERT). Treatment of PD is very expensive and data about social-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::b6c984f75e2d0e3cdf8bd03a93262a56
https://www.clinvest.ru/jour/article/view/425
https://www.clinvest.ru/jour/article/view/425
Autor:
A. A. Kolbin, M. V. Naprienko, A. R. Artemenko, I. A. Vilyum, N. V. Latysheva, M. A. Proskurin, Yu. Ye. Balykina
Publikováno v:
Качественная клиническая практика, Vol 0, Iss 3, Pp 26-44 (2019)
Introduction. Results of both clinical and epidemiological studies demonstrate a high frequency of work incapacity associated with headache, reduced socio-economic activity, low quality of life, greater number of comorbid diseases and mental disorder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::1e5f96ab0927bec89dcc69021ccf67cb
https://www.clinvest.ru/jour/article/view/415
https://www.clinvest.ru/jour/article/view/415
Publikováno v:
Фармакоэкономика, Vol 11, Iss 2, Pp 9-24 (2018)
The aim: to provide a comprehensive pharmacoeconomic evaluation of the maintenance therapy with antipsychotics in outpatients diagnosed with schizophrenia.Materials and methods. The analysis was conducted by two mutually complementary steps: an epide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb249a57301ca67d8c5132a71e2f3ef7
https://www.pharmacoeconomics.ru/jour/article/view/247
https://www.pharmacoeconomics.ru/jour/article/view/247
Publikováno v:
Pharmacoeconomics: theory and practice. 3:22-27
2i/v every 3 weeks. Mathematical modelling underlies this study. As a result it has been demonstrated that the use of vemurafenib strategy in treatment of metastatic melanoma in patients with BRAF V600 mutation had better progression-free survival (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e1e5303fb7e06df7e8b1e186c2bc94d
https://doi.org/10.30809/phe.4.2015.4
https://doi.org/10.30809/phe.4.2015.4